Generic placeholder image

Current Pharmaceutical Biotechnology


ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Research Article

Superior Anticancer Potential of Nano-Paclitaxel Combined Bevacizumab Treatment in Ovarian Cancer

Author(s): Na Qu*, Chunyan Wang, Yiming Meng and Yuhua Gao*

Volume 24, Issue 9, 2023

Published on: 21 October, 2022

Page: [1204 - 1212] Pages: 9

DOI: 10.2174/1389201023666221011115301

Price: $65


Background: Ovarian cancer is the second most common cancer to cause large death among gynecological tumors. Paclitaxel is important to the standard treatment for epithelial ovarian cancer. Due to its low solubility and permeability, nano-paclitaxel came into public view.

Objective: To evaluate the effect of nano-paclitaxel in ovarian cancer.

Methods: Considering the importance of bevacizumab in clinical treatment, we set four groups for research: control, paclitaxel, paclitaxel + bevacizumab, and nano-paclitaxel + bevacizumab. CCK-8, apoptosis, and cell cycle assays were used to detect the cell survival condition. qRT-PCR and western blot were used to detect the gene mRNA and protein expression level. Tumor xenograft in nude mice was used to detect the effect in vivo.

Results: The nano-paclitaxel combined with bevacizumab had the best curative effect. Moreover, the downstream indicators, such as caspases, BAX, FAS, OGFr, PD-L1 and VEGF, changed in four groups, which suggested that the therapy worked by affecting the cell apoptosis, cell cycle, angiogenesis, and immune reaction.

Conclusion: In conclusion, the study helped us better commandof nano-paclitaxel for ovarian cancer treatment and thus could play a role in OC therapy.

Keywords: Paclitaxel, nano-paclitaxel, bevacizumab, ovarian cancer, anticancer, superior.

« Previous

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy